We propose that higher cytoplasmic HIF-2α expression could serve as a useful clinical marker to differentiate paragangliomas from pheochromocytomas, and may help predict outcome in sPGL patients. This evidence concerns the gene EPAS1 and hereditary pheochromocytoma-paraganglioma.